Skip to main content
Caplight Logo









Pluvia Biotech

Pluvia Biotech

Private
BergenHealthcare & Life Scienceshttps://pluviabiotech.com/

Last Round

Seed

May 19, 2026

Total Funding Raised

$1.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Pluvia Biotech is a biotechnology company that develops oral pharmacological chaperones for the treatment of rare genetic disorders caused by protein misfolding, such as phenylketonuria (PKU).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

pharmacological chaperonesphenylketonuriaPKUrare disease drugorphan drugprotein misfoldingsmall-molecule drugbiotech spin-outdrug discoverypreclinical developmentmetabolic disordertherapeutic candidaterare disease biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pluvia Biotech Comparables

Compare Pluvia Biotech with similar companies based on industry and business-model similarity.

Pluvia Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Atlas Molecular Pharma
82%
SOM Biotech
81%
Otsuka Holdings
75%

Pluvia Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 19, 2026
GrantNov 25, 2025
SeedMar 1, 2017

Key People

Founding team and executive leadership

Torgeir Vaage

Chief Financial Officer

Executive Team

Pluvia Biotech Investors

Notable investors and investment history

Pluvia Biotech investors
InvestorRounds
InvestinorSeed
Tidligfasekapital VestlandSeed
Trond Mohn Research FoundationSeed
SarsiaSeed
MABASeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 19, 2026

    Secured Seed funding from Investinor, Sarsia, and others.

  • Oct 27, 2024

    Monthly visitors grew 40% MoM, from 860 to 1.2K.

Pluvia Biotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pluvia Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pluvia Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersBergen
Employee Range10
Year Founded2015
Last FundingMay 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?